Srikant Viswanadha

Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents

Remya Ramesh, Rahul D. Shingare, Vinod Kumar et al. · European Journal of Medicinal Chemistry · 2016 · 79 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530

Silvia L. Locatelli, Giuseppa Careddu, Simone Serio et al. · Clinical Cancer Research · 2018 · 78 citations

Medicine, Oncology, Pharmacology +14

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Auris Huen, Bradley M. Haverkos, Jasmine M. Zain et al. · Cancers · 2020 · 63 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +15

Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC–MS/MS: Application to a pharmacokinetic study

Sridhar Veeraraghavan, Srikant Viswanadha, Satheeshmanikandan Thappali et al. · Journal of Pharmaceutical and Biomedical Analysis · 2014 · 59 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure

B. Seetharamsingh, Remya Ramesh, Santoshkumar S. Dange et al. · ACS Medicinal Chemistry Letters · 2015 · 54 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16